C
Caretha L. Creasy
Researcher at GlaxoSmithKline
Publications - 51
Citations - 6889
Caretha L. Creasy is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: EZH2 & Histone H3. The author has an hindex of 26, co-authored 51 publications receiving 5849 citations. Previous affiliations of Caretha L. Creasy include Drexel University & Pennsylvania State University.
Papers
More filters
Journal ArticleDOI
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
Michael T. McCabe,Heidi M. Ott,Gopinath Ganji,Susan Korenchuk,Christine Thompson,Glenn S. Van Aller,Yan Liu,Alan P. Graves,Anthony Della Pietra,Elsie Diaz,Louis V. LaFrance,Mellinger Mark,Celine Duquenne,Xinrong Tian,Ryan G. Kruger,Charles F. McHugh,Martin Brandt,William H. Miller,Dashyant Dhanak,Sharad K. Verma,Peter J. Tummino,Caretha L. Creasy +21 more
TL;DR: GSK126, a potent, highly selective, S-adenosyl-methionine-competitive, small-molecule inhibitor of EZH2 methyltransferase activity, decreases global H3K27me3 levels and reactivates silenced PRC2 target genes and markedly inhibits the growth of EzH2 mutant DLBCL xenografts in mice are demonstrated.
Journal ArticleDOI
EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
Wendy Béguelin,Relja Popovic,Matt Teater,Yanwen Jiang,Karen L. Bunting,Monica Rosen,Hao Shen,Shao Ning Yang,Ling Wang,Teresa Ezponda,Eva Martinez-Garcia,Haikuo Zhang,Yupeng Zheng,Sharad K. Verma,Michael T. McCabe,Heidi M. Ott,Glenn S. Van Aller,Ryan G. Kruger,Yan Liu,Charles F. McHugh,David Scott,Young Rock Chung,Neil L. Kelleher,Rita Shaknovich,Caretha L. Creasy,Randy D. Gascoyne,Kwok-Kin Wong,Leandro Cerchietti,Ross L. Levine,Omar Abdel-Wahab,Jonathan D. Licht,Olivier Elemento,Ari Melnick +32 more
TL;DR: GC B cell (GCB)-type diffuse large B cell lymphomas (DLBCLs) are mostly addicted to EZH2 but not the more differentiated activated B cell(ABC)-type DLBCLS, thus clarifying the therapeutic scope of EZh2 targeting.
Journal ArticleDOI
The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a Reaper-like motif
L. Miguel Martins,Ingram Iaccarino,Tencho Tenev,Stephen Gschmeissner,Nicholas F. Totty,Nicholas R. Lemoine,John Savopoulos,Carol W. Gray,Caretha L. Creasy,Colin Dingwall,Julian Downward +10 more
TL;DR: The serine protease Omi/HtrA2 is identified as a second mammalian XIAP-binding protein with a Reaper-like motif, and this protease autoprocesses to form a protein with amino-terminal homology to Smac/DIABLO and Reaper family proteins.
Journal ArticleDOI
Epigenomic alterations define lethal CIMP-positive ependymomas of infancy
Stephen C. Mack,Hendrik Witt,Rosario M. Piro,L. Gu,Scott Zuyderduyn,Adrian M. Stütz,Xin Wang,Marco Gallo,Livia Garzia,Kory Zayne,Xiaoyang Zhang,Vijay Ramaswamy,Natalie Jäger,David T.W. Jones,Martin Sill,T. J. Pugh,Marina Ryzhova,Khalida Wani,David Shih,Renee Head,Marc Remke,Swneke D. Bailey,Thomas Zichner,Claudia C. Faria,Mark Barszczyk,Sebastian Stark,Huriye Seker-Cin,Sonja Hutter,Pascal Johann,Sebastian Bender,Volker Hovestadt,Theophilos Tzaridis,Adrian M. Dubuc,Paul A. Northcott,John Peacock,Kelsey C. Bertrand,Sameer Agnihotri,Florence M.G. Cavalli,Ian D. Clarke,K. Nethery-Brokx,Caretha L. Creasy,Sharad K. Verma,Jan Koster,Xiaochong Wu,Yuan Yao,Till Milde,Patrick Sin-Chan,Jennifer Zuccaro,Loretta Lau,Sergio L. Pereira,Pedro Castelo-Branco,Martin Hirst,Marco A. Marra,Stephen S. Roberts,Daniel W. Fults,Luca Massimi,Yoon Jae Cho,T. Van Meter,Wiesława Grajkowska,Boleslaw Lach,Andreas E. Kulozik,A. von Deimling,Olaf Witt,Stephen W. Scherer,Xing Fan,Karin M. Muraszko,Marcel Kool,Scott L. Pomeroy,Nalin Gupta,Joanna J. Phillips,Annie Huang,Uri Tabori,Cynthia Hawkins,David Malkin,Paul Kongkham,William A. Weiss,Nada Jabado,James T. Rutka,Eric Bouffet,Jan O. Korbel,Mathieu Lupien,Kenneth Aldape,Gary D. Bader,Roland Eils,Peter Lichter,Peter B. Dirks,Stefan M. Pfister,Andrey Korshunov,Michael D. Taylor +88 more
TL;DR: It is concluded that epigenetic modifiers are the first rational therapeutic candidates for this deadly malignancy, which is epigenetically deregulated but genetically bland.
Journal ArticleDOI
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)
Michael T. McCabe,Alan P. Graves,Gopinath Ganji,Elsie Diaz,Wendy S. Halsey,Yong Jiang,Kimberly N. Smitheman,Heidi M. Ott,Melissa B. Pappalardi,Kimberly E. Allen,Stephanie Chen,Anthony Della Pietra,Edward Dul,Ashley M. Hughes,Seth A. Gilbert,Sara H. Thrall,Peter J. Tummino,Ryan G. Kruger,Martin Brandt,Benjamin J. Schwartz,Caretha L. Creasy +20 more
TL;DR: This mutation highlights the interplay between Y641 and A677 residues in the substrate specificity of EZH2 and identifies another lymphoma patient population that harbors an activating mutation of EzH2.